Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study Combining NeoVax, a Personalized NeoAntigen Cancer Vaccine, With Ipilimumab to Treat High-risk Renal Cell Carcinoma

NCT02950766 is registered in ClinicalTrials.gov with Patrick Ott, MD, PhD as lead sponsor.

NCT NCT02950766
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02950766 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study Combining NeoVax, a Personalized NeoAntigen Cancer Vaccine, With Ipilimumab to Treat High-risk Renal Cell Carcinoma
Lead sponsor
Patrick Ott, MD, PhD
Phase
Phase 1
Overall status
Active, not recruiting
Start date
March 3, 2019
Completion date
May 30, 2030
Enrollment
19 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

kidney cancer